3-(吡啶-4-基)苯甲醛 | 208190-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(吡啶-4-基)苯甲醛
• 中文别名: 3-吡啶-4-基苯甲醛
• 英文名称: 3-(pyridin-4-yl)benzaldehyde
• 英文别名: 3-pyridin-4-ylbenzaldehyde
• CAS: 208190-04-9
• 化学式: C₁₂H₉NO
• mdl: MFCD02684105
• 分子量: 183.21
• InChiKey: ANVUAAJNQXEBNM-UHFFFAOYSA-N

物化性质

• 熔点：
  48 °C
• 沸点：
  341.8±25.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933399090
• 安全说明：
  S22,S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Pyrid-4-ylbenzaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Pyrid-4-ylbenzaldehyde
CAS number: 208190-04-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H9NO
Molecular weight: 183.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(吡啶-4-基)苯甲醛 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 生成 3-(pyridin-4-yl)benzaldehyde oxime hydrochloride
  参考文献：
  名称：

  Process for the preparation of tryptase inhibitors

  摘要：

  该发明涉及制备式I化合物及其盐的过程，这些化合物可用作曲激酶抑制剂，还涉及制备这些化合物的有用中间体、制备这些中间体的过程，以及利用这些中间体制备这些化合物的用途。

  公开号：

  EP1571150A1
• 作为产物：
  描述：

  间溴苯甲醛 、 吡啶-4-硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 72.0h， 以81%的产率得到3-(吡啶-4-基)苯甲醛
  参考文献：
  名称：

  三种新型镉 3D 配位聚合物的合成、晶体结构和发光性能

  摘要：

  新的刚性平面配体2,5-双(3-(吡啶-4-基)苯基)噻唑并[5,4-d]噻唑(BPPT)已被合成，它是组装配位聚合物的极好基础。在溶剂热反应条件下，镉离子与 BPPT 在各种羧酸（包括 (1,1'-联苯)-4,4'-二羧酸 (BPDC)、间苯二甲酸 (IP) 和苯-1,3）存在下， 5-三羧酸 (BTC) 产生了三种配位配合物，即 [Cd(BPPT)(BPDA)](BPPT)n (1)、[Cd(BPPT) (IP)] (CH3OH) (2) 和[Cd3(BPPT)3(BTC)2(H2O)2] (3)。1、2和3的结构通过单晶X射线衍射表征。还研究了红外光谱以及热重和发光特性。复合物 1 是一个二维 (2D) 网络，并通过 π-π 堆叠相互作用进一步拉伸为 3D 超分子结构。复合体 2 和 3 显示了 3D 框架。配合物1、2和3在室温下表现出发光特性。

  DOI：

  10.3390/molecules25112465

文献信息

• Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D
  作者：Zhen Fang、Yang Liu、Rong Zhang、Qiang Chen、Tianqi Wang、Wei Yang、Yan Fan、Chundong Yu、Rong Xiang、Shengyong Yang

  DOI：10.1016/j.ejmech.2021.113662

  日期：2021.11

  Histone lysine demethylase 4D (KDM4D) plays an important role in the regulation of tumorigenesis, progression and drug resistance and has been considered a potential target for cancer treatment. However, there is still a lack of potent and selective KDM4D inhibitors. In this investigation, we report a new class of KDM4D inhibitors containing the 2-(aryl (pyrrolidine-1-yl)methyl)phenol scaffold, identified

  组蛋白赖氨酸脱甲基酶 4D (KDM4D) 在调节肿瘤发生、进展和耐药性方面发挥着重要作用，被认为是癌症治疗的潜在靶点。然而，仍然缺乏有效和选择性的 KDM4D 抑制剂。在这项调查中，我们报告了一类新的 KDM4D 抑制剂，其中包含 2-（芳基（吡咯烷-1-基）甲基）苯酚支架，通过基于 AlphaLisa 的筛选、结构优化和结构-活性关系分析确定。在这些抑制剂中，24s是最有效的，IC 500.023 ± 0.004 μM 的值。与 KDM4A 以及其他 JMJD 亚家族成员相比，该化合物对 KDM4D 的选择性高出 1500 倍以上，表明对 KDM4D 具有良好的选择性。动力学分析表明，24s不占据 2-酮戊二酸结合口袋。在体外试验中，24s显着抑制了结直肠癌 (CRC) 细胞的增殖和迁移。总的来说，这项研究已经确定了一种很好的工具化合物来探索 KDM4D 的生物学功能，以及一种很好的先导化合物，用于靶向
• NOVEL OPIOID ANTAGONISTS
  申请人：Dolle E. Roland

  公开号：US20070105863A1

  公开（公告）日：2007-05-10

  Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.

  某些喹诺里西啶和八氢吡啶吡嗪化合物、药物组合物及其使用方法被披露，例如作为阿片受体拮抗剂。
• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。
• Synthesis and characterization of Sant-75 derivatives as Hedgehog-pathway inhibitors
  作者：Chao Che、Song Li、Bo Yang、Shengchang Xin、Zhixiong Yu、Taofeng Shao、Chuanye Tao、Shuo Lin、Zhen Yang

  DOI：10.3762/bjoc.8.94

  日期：——

  Sant-75 is a newly identified potent inhibitor of the hedgehog pathway. We designed a diversity-oriented synthesis program, and synthesized a series of Sant-75 analogues, which lays the foundation for further investigation of the structure–activity relationship of this important class of hedgehog-pathway inhibitors.

  Sant-75是一种新发现的对刺猬途径具有强大抑制作用的抑制剂。我们设计了一个多样性定向合成计划，并合成了一系列Sant-75类似物，为进一步研究这一重要类别的刺猬途径抑制剂的结构-活性关系奠定了基础。
• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。